Display options
Share it on

BMC Blood Disord. 2004 Mar 02;4:1. doi: 10.1186/1471-2326-4-1. eCollection 2004.

Expression of the 60 kDa and 71 kDa heat shock proteins and presence of antibodies against the 71 kDa heat shock protein in pediatric patients with immune thrombocytopenic purpura.

BMC blood disorders

Chengfeng Xiao, Sheng Chen, Mingchun Yuan, Fuyue Ding, Dongliang Yang, Ruibo Wang, Jianxin Li, Robert M Tanguay, Tangchun Wu

Affiliations

  1. Institute of Occupational Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  2. Department of Haematological Diseases, Wuhan Children Hospital, Wuhan 430015, China.
  3. Division of Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,1095 Jiefang Avenue, Wuhan 430030, China.
  4. Laboratory of Cell and Developmental Genetics, Dept Medicine, Faculty of Medicine, Pavillon Marchand, Université Laval, Québec, Canada, G1K 7P4.

PMID: 15070425 PMCID: PMC385232 DOI: 10.1186/1471-2326-4-1

Abstract

BACKGROUND: Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by platelet destruction resulting from autoantibodies against platelet proteins, particularly platelet glycoprotein IIb/IIIa. Heat shock proteins (Hsp) have been shown to be major antigenic determinants in some autoimmune diseases. Antibodies to Hsps have also been reported to be associated with a number of pathological states.

METHODS: Using western blot, we measured the levels of the 60 kDa heat shock protein (Hsp60) and of the inducible 71 kDa member of the Hsp70 family (Hsp71) in lymphocytes and the presence of antibodies against these hsps in plasma of 29 pediatric patients with ITP before the treatment and in 6 other patients before and after treatment.

RESULTS: Interestingly only one out of 29 patients showed detectable Hsp60 in lymphocytes while this heat shock protein was detected in the 30 control children. Hsp71 levels were slightly lower in lymphocytes of patients with ITP than in controls (1567.8 ± 753.2 via 1763.2 ± 641.8 integrated optical density (IOD) units). There was a small increase of Hsp71 after recovery from ITP. The titers of plasma antibodies against Hsp60 and Hsp71 were also examined. Antibodies against Hsp71 were more common in ITP patients (15/29) than in control children (5/30). The titer of anti-Hsp71 was also higher in children patients with ITP. The prevalence of ITP children with antibodies against Hsp71 (51.7%) was as high as those with antibodies against platelet membrane glycoproteins (58.3%).

CONCLUSIONS: In summary, pediatric patients with ITP showed no detectable expression of Hsp60 in lymphocytes and a high prevalence of antibody against Hsp71 in plasma. These changes add to our understanding of the pathogenesis of ITP and may be important for the diagnosis, prognosis and treatment of ITP.

References

  1. J Clin Invest. 1995 Apr;95(4):1854-60 - PubMed
  2. Semin Hematol. 1999 Jan;36(1 Suppl 1):2-6 - PubMed
  3. Circulation. 1999 Mar 30;99(12):1560-6 - PubMed
  4. Biochem Biophys Res Commun. 1992 May 29;185(1):116-20 - PubMed
  5. J Immunol. 1995 Jan 1;154(1):363-74 - PubMed
  6. J Hepatol. 1995 Oct;23(4):382-90 - PubMed
  7. Cell Mol Life Sci. 1997 Jan;53(1):104-13 - PubMed
  8. N Engl J Med. 2001 Sep 6;345(10):747-55 - PubMed
  9. Physiol Rev. 1992 Oct;72(4):1063-81 - PubMed
  10. Eur J Biochem. 1991 Jul 1;199(1):35-9 - PubMed
  11. N Engl J Med. 2002 Mar 28;346(13):995-1008 - PubMed
  12. Annu Rev Genet. 1988;22:631-77 - PubMed
  13. Immunopharmacology. 2000 Jul 25;48(3):299-302 - PubMed
  14. Immunol Today. 2000 Mar;21(3):129-32 - PubMed
  15. Dev Genet. 1993;14(2):112-8 - PubMed
  16. Am J Physiol. 1993 Dec;265(6 Pt 2):R1447-57 - PubMed
  17. Cell. 1991 Jul 26;66(2):191-7 - PubMed
  18. Cell Stress Chaperones. 1997 Sep;2(3):162-7 - PubMed
  19. Drug Discov Today. 2000 Mar;5(3):115-120 - PubMed
  20. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14 ):7841-6 - PubMed
  21. J Biol Chem. 2001 Aug 17;276(33):31332-9 - PubMed
  22. Biol Chem. 2001 Apr;382(4):629-36 - PubMed
  23. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1681-5 - PubMed
  24. Cell Stress Chaperones. 2001 Apr;6(2):113-20 - PubMed
  25. J Bacteriol. 1997 Jul;179(13):4403-6 - PubMed
  26. Blood. 2001 Sep 15;98(6):1852-7 - PubMed
  27. Circulation. 1999 Sep 14;100(11):1169-74 - PubMed
  28. Cell. 2001 Sep 7;106(5):551-61 - PubMed
  29. Nature. 1992 Jan 2;355(6355):33-45 - PubMed
  30. Blood. 1989 Oct;74(5):1600-2 - PubMed
  31. Acta Paediatr Suppl. 1998 Jun;424:16-20 - PubMed
  32. Crit Rev Immunol. 1993;13(1):71-81 - PubMed
  33. Blood. 1993 Jun 1;81(11):2872-7 - PubMed
  34. Immunity. 1998 Jun;8(6):657-65 - PubMed
  35. J Clin Invest. 1995 Jan;95(1):3-12 - PubMed
  36. J Biol Chem. 1996 Jul 12;271(28):16833-41 - PubMed
  37. Circulation. 1993 Mar;87(3):963-71 - PubMed
  38. Semin Cancer Biol. 1995 Dec;6(6):349-55 - PubMed
  39. Hematology Am Soc Hematol Educ Program. 2000;:222-240 - PubMed
  40. Nat Med. 2000 Apr;6(4):435-42 - PubMed
  41. Cell Stress Chaperones. 1998 Sep;3(3):161-7 - PubMed
  42. Cell Stress Chaperones. 2001 Oct;6(4):394-401 - PubMed
  43. J Clin Invest. 1995 Apr;95(4):1446-56 - PubMed
  44. Ann N Y Acad Sci. 1998 Sep 29;856:206-13 - PubMed
  45. Curr Opin Pediatr. 1997 Feb;9(1):35-40 - PubMed
  46. Hypertension. 1997 Jan;29(1 Pt 1):40-4 - PubMed

Publication Types